Get the Stockscreener App
37.10
1.22%
-0.46
After Hours:
37.02
-0.08
-0.22%
Ptc Therapeutics Inc stock is traded at $37.10, with a volume of 1.14M.
It is down -1.22% in the last 24 hours and up +5.04% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
See More
Previous Close:
$37.56
Open:
$37.5
24h Volume:
1.14M
Relative Volume:
1.98
Market Cap:
$2.85B
Revenue:
$900.45M
Net Income/Loss:
$-479.52M
P/E Ratio:
-4.289
EPS:
-8.65
Net Cash Flow:
$-230.14M
1W Performance:
+0.95%
1M Performance:
+5.04%
6M Performance:
+27.54%
1Y Performance:
+65.55%
1-Day Range:
$36.83
$37.87
1-Week Range:
$36.26
$38.62
52-Week Range:
$17.53
$40.69
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
Barclays Maintains PTC Therapeutics (PTCT) Equal-Weight Recommendation - MSN
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Boosted by Armistice Capital LLC - MarketBeat
PTC Therapeutics' Huntington's Treatment Gets FDA Fast Track Designation - MarketWatch
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program - StockTitan
Duchenne Muscular Dystrophy Treatment Market Will Accelerate - openPR
XTX Topco Ltd Makes New $947,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
(PTCT) Technical Pivots with Risk Controls - Stock Traders Daily
Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $37.64 - MarketBeat
Renaissance Technologies LLC Boosts Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Rating Reiterated by Cantor Fitzgerald - MarketBeat
Leigh Syndrome Market Growth to Accelerate in Forecast Period - openPR
PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 5.7% - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value (PTCT) - Seeking Alpha
Bank of New York Mellon Corp Purchases 40,840 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Lifted by Bank of New York Mellon Corp - Defense World
PTC Therapeutics (NASDAQ:PTCT investor five-year losses grow to 27% as the stock sheds US$153m this past week - Simply Wall St
Allspring Global Investments Holdings LLC Has $31,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - Defense World
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Cowen AND Company LLC - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Upgraded by Baird R W - Defense World
TD Cowen maintains hold on PTC Therapeutics with $33 target - Investing.com India
PTC Therapeutics (NASDAQ:PTCT) Shares Down 4.6% - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Strong-Buy at Baird R W - MarketBeat
Rett Syndrome Market Expected to Experience Major Growth - openPR
Robert W. Baird Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT) - MarketBeat
Friedreich's Ataxia Market to Show Remarkable Growth Trends - openPR
Panagora Asset Management Inc. Raises Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Panagora Asset Management Inc. Has $9.64 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - Defense World
PTC Therapeutics to Participate at Upcoming Investor Conferences - StockTitan
ClearPoint Neuro Announces Early Repayment of $10 Million Note - GlobeNewswire
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Hold" by Brokerages - MarketBeat
PTC Therapeutics rises as UBS restarts coverage with buy rating - MSN
PTC Therapeutics (NASDAQ:PTCT) Earns Buy Rating from Analysts at UBS Group - MarketBeat
UBS Group Begins Coverage on PTC Therapeutics (NASDAQ:PTCT) - Defense World
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of “Hold” from Analysts - Defense World
PTC Therapeutics (NASDAQ:PTCT) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
Neo Ivy Capital Management Invests $1.25 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Duchenne Muscular Dystrophy Treatment Market Statistical - openPR
PTCT (PTC Therapeutics) COGS-to-Revenue : 0.08 (As of Jun. 2024) - GuruFocus.com
PTCT (PTC Therapeutics) EPS (Basic) : $-6.31 (TTM As of Jun. 2024) - GuruFocus.com
PTCT (PTC Therapeutics) Cash From Other Investing Activitie - GuruFocus.com
PTCT (PTC Therapeutics) Inventories, Raw Materials & Components : $1.1 Mil (As of Jun. 2024) - GuruFocus.com
PTC Therapeutics : Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation - Marketscreener.com
Assenagon Asset Management S.A. Purchases 66,596 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTCT (PTC Therapeutics) Cost of Goods Sold : $68.9 Mil (TTM As of Jun. 2024) - GuruFocus.com
PTCT (PTC Therapeutics) Market Cap : $2,541.6 Mil (As of Aug. 16, 2024) - GuruFocus.com
PTCT (PTC Therapeutics) Issuance of Debt : $0.0 Mil (TTM As of Jun. 2024) - GuruFocus.com
When (PTCT) Moves Investors should Listen - Stock Traders Daily
Diversified Trust Co Has $468,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - Defense World
Brokers Issue Forecasts for PTC Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:PTCT) - MarketBeat
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):